Investor Relations

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.


News Release

 View printer-friendly version

Charles River Laboratories Announces Intention to File a Registration Statement

WILMINGTON, Mass.--(BW HealthWire)--June 22, 2001--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it intends to file a registration statement with the Securities and Exchange Commission on June 25, 2001 for a proposed underwritten offering of 8,000,000 shares of its common stock, plus an additional 1,200,000 shares to cover over-allotments if the underwriters exercise the over-allotment option. The Company will sell 2,000,000 shares and selling shareholders will sell the remaining 6,000,000 shares and the 1,200,000 over-allotment shares, if any.

This release is not an offer to sell or a solicitation of an offer to buy any of these securities.


CONTACT: Charles River Laboratories International, Inc.
Dennis Shaughnessy
978/658-6000 x.1207

Featured Report

2020 Annual Report (PDF)

Charles River Corporate Citizenship Report
View PDF
Print PDF